2026-W46 · Nov 9–Nov 15 · Company · Profile · published
IQVIA company profile · clinical research, health data & analytics · history · financial snapshot · S&P 500 rank #254 · 艾昆緯公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | IQV (NYSE) |
| Company | IQVIA Holdings Inc. |
| GICS sector / industry | Health Care (XLV) / Life Sciences Tools & Services |
| S&P 500 rank (by weight) | #254 · 0.06% (Nov 2, 2026) |
| Sector rank (by S&P 500 weight) | #33 in Health Care (Nov 2, 2026) |
| Headquarters | Durham, North Carolina |
| Founded | 1982 (Quintiles); IMS Health founded 1954 |
| CEO | Ari Bousbib (chairman and CEO) |
| Employees | Approximately 89,000 (31,000 Technology & Analytics + 51,000 R&D Solutions + 7,000 Contract Sales & Medical) |
| Market cap | $44.06B (Nov 2, 2026) |
| SEC filings | EDGAR — CIK 0001478242 |
WHAT IT DOES
IQVIA combines contract clinical research with one of the world’s largest healthcare data sets. Drug developers hire it to run trials and, separately, buy its prescription, claims and real-world data to plan launches, price drugs and target physicians.
Research & Development Solutions — running trials — is the largest segment. Technology & Analytics Solutions sells data, software and analytics on subscription, and Contract Sales & Medical Solutions provides outsourced sales teams.
FY2025 total revenues were $16,310M versus $15,405M in FY2024, net income attributable to IQVIA Holdings Inc. was $1,360M and diluted EPS was $7.84. About 89,000 people work across the three segments.
BUSINESS SEGMENTS — FY2025 REVENUES
| Segment | Revenues | Share | YoY |
|---|---|---|---|
| Research & Development Solutions | $8,896M | 54.5% | — |
| Technology & Analytics Solutions | $6,626M | 40.6% | — |
| Contract Sales & Medical Solutions | $788M | 4.8% | — |
HISTORY
| Year | Milestone |
|---|---|
| 1954 | IMS Health founded, building prescription audit data. |
| 1982 | Quintiles founded as a clinical research organisation. |
| 2016 | IMS Health and Quintiles merge, forming QuintilesIMS. |
| 2017 | Renamed IQVIA and listed on the New York Stock Exchange. |
| 2025 | FY2025 revenues $16,310M, up from $15,405M in FY2024. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Total revenues | $16,310M (vs $15,405M in FY2024) |
| Net income attributable to IQVIA Holdings Inc. | $1,360M |
| Diluted EPS | $7.84 |
| Employees | Approximately 89,000 |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
IQVIA is the data layer of drug development: its trial backlog and data subscriptions track pharmaceutical R&D spending before it shows up in drug sales.
At S&P 500 rank #254 with a 0.06% weight, it represents life sciences tools and services inside Health Care.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Nov 2, 2026 crawl) · StockAnalysis (market cap — Nov 2, 2026 crawl, single source) |
| Financials | IQVIA Form 10-K FY2025 (filed Feb 17, 2026), consolidated statements and segment note |
| Sector classification | GICS via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | IQV(NYSE) |
| 公司 | IQVIA Holdings Inc. |
| GICS 板塊/行業 | 健康護理(XLV)/Life Sciences Tools & Services |
| 標普500排名(按權重) | 第254名 · 0.06%(2026 年 11 月 2 日) |
| 板塊內排名(按標普500權重) | 健康護理第33名(2026 年 11 月 2 日) |
| 總部 | 北卡羅來納州達勒姆 |
| 成立 | 1982年(Quintiles);IMS Health 成立於1954年 |
| 行政總裁 | Ari Bousbib(董事長兼行政總裁) |
| 員工 | 約89,000人(技術與分析31,000人+研發解決方案51,000人+合約銷售與醫療7,000人) |
| 市值 | $44.06B(2026 年 11 月 2 日) |
| SEC 文件 | EDGAR — CIK 0001478242 |
業務概覽
艾昆緯結合合約臨床研究與全球最大的醫療數據集之一。藥企聘請其執行試驗,同時購買其處方、理賠與真實世界數據,用於規劃上市、定價與醫生覆蓋。
研發解決方案(執行試驗)為最大板塊。技術與分析解決方案以訂閱制銷售數據、軟件與分析;合約銷售與醫療解決方案提供外包銷售團隊。
FY2025 總收入 163.10 億美元,FY2024 為 154.05 億美元;艾昆緯控股公司應佔淨利潤 13.60 億美元,攤薄每股收益 7.84 美元。三個板塊共約 89,000 名員工。
業務板塊 — FY2025 收入
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 研發解決方案 | $8,896M | 54.5% | — |
| 技術與分析解決方案 | $6,626M | 40.6% | — |
| 合約銷售與醫療解決方案 | $788M | 4.8% | — |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1954 | IMS Health 成立,建立處方審計數據。 |
| 1982 | Quintiles 成立為臨床研究機構。 |
| 2016 | IMS Health 與 Quintiles 合併,組成 QuintilesIMS。 |
| 2017 | 更名為 IQVIA,於紐約證券交易所上市。 |
| 2025 | FY2025 收入 163.10 億美元,高於 FY2024 的 154.05 億美元。 |
競爭地位
財務快照 — FY2025
| 總收入 | $16,310M(FY2024 為 $15,405M) |
| 艾昆緯控股公司應佔淨利潤 | $1,360M |
| 攤薄每股收益 | $7.84 |
| 員工 | 約89,000人 |
主要風險
對標普500的重要性
艾昆緯是藥物開發的數據層:其試驗積壓與數據訂閱先於藥品銷售反映製藥研發開支。
標普500排名第254位、權重 0.06%,代表健康護理板塊內的生命科學工具與服務行業。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 2 日抓取)· StockAnalysis(市值——2026 年 11 月 2 日抓取,單一來源) |
| 財務 | 艾昆緯 FY2025 10-K(2026 年 2 月 17 日提交),合併報表與板塊附註 |
| 板塊分類 | GICS,據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-01 20:11 · updated 2026-11-14 23:40 · rev 5